相似文献
1
Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool.
Immunol Rev. 2015 Mar;264(1):363-81. doi: 10.1111/imr.12270.
2
The use of mutant mycobacteria as new vaccines to prevent tuberculosis.
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):203-10. doi: 10.1016/j.tube.2006.01.022. Epub 2006 Mar 20.
3
Novel tuberculosis vaccines on the horizon.
Curr Opin Immunol. 2010 Jun;22(3):374-84. doi: 10.1016/j.coi.2010.04.006. Epub 2010 May 12.
4
Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity.
Clin Immunol. 2007 Mar;122(3):239-51. doi: 10.1016/j.clim.2006.10.010. Epub 2007 Jan 5.
5
Fact and fiction in tuberculosis vaccine research: 10 years later.
Lancet Infect Dis. 2011 Aug;11(8):633-40. doi: 10.1016/S1473-3099(11)70146-3.
6
Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?
Hum Vaccin Immunother. 2016 May 3;12(5):1193-5. doi: 10.1080/21645515.2015.1136760. Epub 2016 Apr 6.
7
New hope for tuberculosis vaccines.
Lancet Infect Dis. 2019 Jul;19(7):687-688. doi: 10.1016/S1473-3099(19)30280-4.
8
Tuberculosis vaccine research: the impact of immunology.
Curr Opin Immunol. 2009 Jun;21(3):331-8. doi: 10.1016/j.coi.2009.05.017. Epub 2009 Jun 7.
9
Advances in tuberculosis vaccine strategies.
Nat Rev Microbiol. 2006 Jun;4(6):469-76. doi: 10.1038/nrmicro1419.
10
The role of immunoinformatics in the development of T-cell peptide-based vaccines against .
Expert Rev Vaccines. 2020 Sep;19(9):831-841. doi: 10.1080/14760584.2020.1825950. Epub 2020 Oct 8.
引用本文的文献
1
Molecular mechanisms of immune evasion by host protein glycosylation of a bacterial immunogen used in nucleic acid vaccines.
bioRxiv. 2025 May 30:2025.05.29.656815. doi: 10.1101/2025.05.29.656815.
2
Host and pathogen genetic diversity shape vaccine-mediated protection to .
Front Immunol. 2024 Jun 28;15:1427846. doi: 10.3389/fimmu.2024.1427846. eCollection 2024.
3
A novel multistage antigens ERA005f confer protection against by driving Th-1 and Th-17 type T cell immune responses.
Front Immunol. 2023 Nov 7;14:1276887. doi: 10.3389/fimmu.2023.1276887. eCollection 2023.
4
Assessing vaccine-mediated protection in an ultra-low dose Mycobacterium tuberculosis murine model.
PLoS Pathog. 2023 Nov 27;19(11):e1011825. doi: 10.1371/journal.ppat.1011825. eCollection 2023 Nov.
5
Comparative immune responses to in people with latent infection or sterilizing protection.
iScience. 2023 Jul 20;26(8):107425. doi: 10.1016/j.isci.2023.107425. eCollection 2023 Aug 18.
6
It Takes a Village: The Multifaceted Immune Response to Infection and Vaccine-Induced Immunity.
Front Immunol. 2022 Mar 10;13:840225. doi: 10.3389/fimmu.2022.840225. eCollection 2022.
7
Understanding the tuberculosis granuloma: the matrix revolutions.
Trends Mol Med. 2022 Feb;28(2):143-154. doi: 10.1016/j.molmed.2021.11.004. Epub 2021 Dec 15.
8
Ultra-low Dose Aerosol Infection of Mice with Mycobacterium tuberculosis More Closely Models Human Tuberculosis.
Cell Host Microbe. 2021 Jan 13;29(1):68-82.e5. doi: 10.1016/j.chom.2020.10.003. Epub 2020 Nov 2.
9
Plant-Produced N-glycosylated Ag85A Exhibits Enhanced Vaccine Efficacy Against HN878 Through Balanced Multifunctional Th1 T Cell Immunity.
Vaccines (Basel). 2020 Apr 18;8(2):189. doi: 10.3390/vaccines8020189.
10
First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment.
Vaccines (Basel). 2019 Nov 1;7(4):166. doi: 10.3390/vaccines7040166.
本文引用的文献
1
mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity.
Science. 2014 Sep 26;345(6204):1250684. doi: 10.1126/science.1250684.
2
Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-γ for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages.
J Immunol. 2014 Oct 1;193(7):3600-12. doi: 10.4049/jimmunol.1401088. Epub 2014 Sep 3.
3
Tuberculin skin test negativity is under tight genetic control of chromosomal region 11p14-15 in settings with different tuberculosis endemicities.
J Infect Dis. 2015 Jan 15;211(2):317-21. doi: 10.1093/infdis/jiu446. Epub 2014 Aug 20.
4
KLRG+ invariant natural killer T cells are long-lived effectors.
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12474-9. doi: 10.1073/pnas.1406240111. Epub 2014 Aug 12.
5
Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis.
BMJ. 2014 Aug 5;349:g4643. doi: 10.1136/bmj.g4643.
6
Every breath you take: the impact of environment on resident memory CD8 T cells in the lung.
Front Immunol. 2014 Jul 8;5:320. doi: 10.3389/fimmu.2014.00320. eCollection 2014.
7
A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells.
J Exp Med. 2014 Jul 28;211(8):1585-600. doi: 10.1084/jem.20140484. Epub 2014 Jul 21.
8
MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage.
J Exp Med. 2014 Jul 28;211(8):1601-10. doi: 10.1084/jem.20140507. Epub 2014 Jul 21.
9
Innovative Strategies to Identify M. tuberculosis Antigens and Epitopes Using Genome-Wide Analyses.
Front Immunol. 2014 Jun 25;5:256. doi: 10.3389/fimmu.2014.00256. eCollection 2014.
10
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk.
Nature. 2014 Jul 3;511(7507):99-103. doi: 10.1038/nature13489. Epub 2014 Jun 25.
Zotero 插件